Interventional approach to reduce thromboembolic risk in patents with atrial fibrillation ineligible for oral anticoagulation

Italian Heart Journal

Volumn 6, Issue 5, 2005, Pages 414-417

  Ramondo, Angelo ^a   Maiolino, Giuseppe ^a   Napodano, Massimo ^a   Isabella, Gianbattista ^a   Tarantini, Giuseppe ^a   Bonato, Raffaele ^a   Pengo, Vittorio ^a   Ponchia, Andrea ^a   Iliceto, Sabino ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticoagulants; Atrial fibrillation; Left atrial appendage

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ARTICLE; BALLOON OCCLUSION; CASE REPORT; DRUG CONTRAINDICATION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HUMAN; INSTRUMENTATION; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RISK FACTOR; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BALLOON OCCLUSION; HEART CATHETERIZATION; HUMANS; MALE; RISK FACTORS; THROMBOEMBOLISM;

EID: 23844459583     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-61.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987; 147: 1561-4.
3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-84.
4. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; 1: 526-9.
5. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham study. Am Heart J 1983; 106: 389-96.
6. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-22.
7. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38: 1231-66.
8. Ansell J, Hish J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the. vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl): 204S-233S.
9. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 1231-3.
10. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials, translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945-53.
11. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-9.
12. Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99: 3028-35.
13. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317: 669-74.
14. Madden JL. Resection of the left auricular appendix. JAMA 1948; 140: 769-72.
15. Bonow RO, Carabello B, de Leon AC Jr, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on management of patients with valvular heart disease). Circulation 1998; 98: 1949-84.
16. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg 2000; 17: 718-22.
17. Bando K, Kobayashi J, Hirata M, et al. Early and lake stroke after mitral valve replacement with a mechanical prosthesis risk factor analysis of a 24-year experience. J Thorac Cardiovasc Surg 2003; 126; 358-64.
18. Garcia-Fernandez MA, Petez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis a transesophageal echocandiographic study. J Am Coll Cardiol 2003; 42: 1253-8.
19. Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. J Am Coll Cardiol 2000; 36: 468-71.
20. Stollberger C, Schneider B, Finsterer J. Is left atrial appendage occlusion during routine coronary artery bypass graft surgery useful for stroke prevention? (letter) Am Heart J 2003; 146: E26.
21. Virmani R, Kolodgie FD, Dake MD, et al. Histopathologic evaluation of an expanded polytetrafluoroethylene-nitinol stent endoprosthesis in canine iliofemoral arteries. J Vasc Interv Radiol 1999; 10: 445-56.
22. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002; 105: 1887-9.
23. Hanna IR, Kolm P, Martin R, Reisman M, Gray W, Block PC. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. J Am Coll Cardiol 2004; 43: 1868-72.